Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8217792 | 0.84 | ESR2 (0.46) | ADORA2AADORA1 | |
| SCHEMBL6788959 | 0.84 | ALDH1A1 (0.45) | MAPTALDH1A1IKBKBKDM4EKMO | |
| SCHEMBL20339943 | 0.84 | NPBWR1 (0.40) | NOTUMALDH1A1IKBKBHPGDMEN1 | |
| SCHEMBL4083350 | 0.84 | TSHR (0.39) | NOTUMHRH1MAPTALDH1A1IKBKB | |
| SCHEMBL4399156 | 0.84 | ALDH1A1 (0.52) | HRH1IDO1MAPTALDH1A1IKBKB | |
| SCHEMBL23291740 | 0.84 | KDM4E (0.33) | AHRNOTUMHRH1MAPTKDM4E | |
| SCHEMBL2227390 | 0.81 | KMO (0.58) | AHRNOTUMLMNAKMOHPGD | |
| SCHEMBL20339909 | 0.80 | HRH1 (0.31) | HRH1 | |
| SCHEMBL23451486 | 0.80 | NOTUM (0.56) | NOTUM | |
| SCHEMBL2679082 | 0.80 | HRH1 (0.37) | HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070021330-A1 | Aza-peptide macrocyclic hepatitis c serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| US-7125845-B2 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050065073-A1 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005010029-A1 | AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | AHR 2731/4885NOTUM 784/4885HRH1 3495/4885 |
| US-20070021330-A1 | Aza-peptide macrocyclic hepatitis c serine protease inhibitors | VIP, CTSC, DPP4 | AHR 3695/4885NOTUM 1810/4885HRH1 3907/4885 |
| US-20050065073-A1 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | VIP, CTSC, PRSS1 | AHR 3791/4885NOTUM 1601/4885HRH1 3754/4885 |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | P2RX1, P2RX3, P2RX7 | AHR 868/4885NOTUM 4789/4885HRH1 523/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | AHR 2675/4885NOTUM 868/4885HRH1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.